Barclays Boosts Encompass Health (NYSE:EHC) Price Target to $118.00

Encompass Health (NYSE:EHC) had its price target increased by equities researchers at Barclays from $116.00 to $118.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 18.17% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on EHC. William Blair reissued an “outperform” rating on shares of Encompass Health in a research note on Friday. KeyCorp increased their target price on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research report on Tuesday, October 29th. Royal Bank of Canada upped their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, Truist Financial reissued a “buy” rating and set a $116.00 price target (up previously from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $107.33.

Encompass Health Stock Performance

NYSE:EHC traded up $1.26 during mid-day trading on Friday, hitting $99.86. The company’s stock had a trading volume of 1,202,525 shares, compared to its average volume of 666,313. Encompass Health has a 1 year low of $72.37 and a 1 year high of $104.55. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The stock has a market cap of $10.06 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 1.18 and a beta of 0.90. The business’s fifty day moving average is $96.34 and its two-hundred day moving average is $95.10.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. Analysts anticipate that Encompass Health will post 4.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Encompass Health

Large investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB boosted its stake in Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after acquiring an additional 137 shares during the period. UMB Bank n.a. grew its stake in Encompass Health by 387.7% during the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after buying an additional 252 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Encompass Health by 53.0% in the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after buying an additional 140 shares during the last quarter. Avior Wealth Management LLC bought a new position in shares of Encompass Health during the third quarter worth about $40,000. Finally, Tompkins Financial Corp bought a new stake in Encompass Health in the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.